Special Considerations in HIV Management : Episode 1

Video

December 27, 2017

Special Considerations in HIV Management

Throughout this AJMC Peer Exchange^®, a panel of experts in infectious disease and managed care will discuss today’s management of HIV, including the need for individualized care and the role for newer treatment options.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Ovarian cancer | Image Credit: tashatuvango - stock.adobe.com

June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa

Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

PrEP | Image credit: Bowonpat - stock.adobe.com

June 24th 2025

Researchers Estimate PrEP Needed in the US Across Multiple Subgroups

Julia Bonavitacola

A model that can estimate the need for pre-exposure prophylaxis (PrEP) in the US can help to clarify use patterns to address HIV in local settings.

June 20th 2025

Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

Julia Bonavitacola Colleen Kelley, MD, MPH

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.